

PLEASE REFER TO SOLID TUMORS CLINICAL TRIAL LIST FOR MORE OPTIONS

HEAD AND NECK

Sponsor/ Protocol ID	clinicaltrials.gov Identifier (NCTxxx)	Study Title	Phase	Name of PI (Hospital)	Study Manager (Hospital)	Study Coordinator (Hospital) Extension MUHC: 514-934-1934 JGH: 514-340-8222	Comments
Advanced Head and Neck							
1	RTOG 0920	NCT00956007	A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for locally-advanced resected Head and Neck Cancer	3	George Shenouda (MUHC)	Marianna Perna (MUHC)	Tatiana Carvalho (MUHC) ext. 43698 Ginette Ricard (MUHC) ext 43186 Josie Pepe (MUHC) ext 48186
					Khalil Sultanem (JGH)	Cindy Rousseau (JGH)	Cindy Rousseau (JGH) ext 25098
2	Glance Merck RCO-1106		Global Treatment Patterns, Health Care Resource Utilization, and Survival Outcomes among Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck		Sultanem (JGH)	Nathalie Thibault 25098 (JGH)	Nathalie Thibault (JGH) ext 25098
Nasopharyngeal							
3	RTOG HN001	NCT02135042	Randomized phase II and phase III studies of individualized treatment for nasopharyngeal carcinoma based on biomarker Epstein Barr Virus (EBV) deoxyribonucleic acid (DNA)	2/3	George Shenouda (MUHC)	Marianna Perna (MUHC)	Tatiana Carvalho (MUHC) ext. 43698 Ginette Ricard (MUHC) ext 43186 Josie Pepe (MUHC) ext 48186
					Khalil Sultanem (JGH)	Cindy Rousseau (JGH)	Cindy Rousseau (JGH) ext 25098
Oropharyngeal							

PLEASE REFER TO SOLID TUMORS CLINICAL TRIAL LIST FOR MORE OPTIONS

4	Investigator Initiated Trial (Dr. Sadeghi and Dr. Siegel)	NCT02760667	A Phase II Study of Induction Chemotherapy Followed by Surgical Treatment in Locally Advanced Oropharyngeal And Supraglottic Cell Carcinom	2	Nader Sadeghi (MUHC)	TBD	ext 34974 (MUHC)	
5	Lawson Health Research D419LC0001 ORATOR	NCT01590355	A Phase II Randomized Trial for Early-stage Squamous Cell Carcinoma of the Oropharynx: Radiotherapy vs Trans-oral Robotic Surgery (ORATOR)	2	Michael Hier (JGH)	Adele Cascini (JGH)	Sabrina Cesare (JGH) ext 24301	
6	RCN		Marching Ahead: Imaging Biomarkers, a new revolution in patient management and care for Human Papilloma Virus (HPV) Positive Oropharyngeal Cancer		Jeffrey Chankowsky (MUHC)			
Squamous Cell (HNSCC)								
7	CR1737MK Merck OPENING SOON		A Phase 3 Randomized, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen as First line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	3	Wilson Miller (JGH)	Adele Cascini (JGH)	Caroline Lambert (JGH) ext 22042	Group 1: Pembro + Epacadostat Group 2: Pembro Group 3: EXTREME Regimen (Cetuximab, cisplatin or carbo, 5-FU)
8	AstraZeneca KESTREL D419LC00001	NCT02369874	Study of MEDI4736 with or without Tremelimumab versus standard of care in recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)	3	Nathaniel Bouganim (MUHC)	Penny Chipman (MUHC)	Marie-Claude Joncas (MUHC) 42560	

PLEASE REFER TO SOLID TUMORS CLINICAL TRIAL LIST FOR MORE OPTIONS

9	MUHC		FDG Positron Emission Tomography (PET) for Early Detection of Response to Chemoradiotherapy (CRT) in Head and Neck Squamous Cell Carcinoma (HNSCC)		Anthony Zeitouni (MUHC)			
10	JGH		Lung cancer surveillance for head and neck patients: A prospective randomized study		Michael Hier (JGH)		25387 (JGH)	Agulnik (resp) and Forghani (radiology)
11	RTOG 3501	NCT01711658	TRYHARD: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (Tykerb®) for Non-HPV Locally Advanced Head and Neck Cancer With Concurrent Chemoradiation	2	George Shenouda (MUHC)	Marianna Perna (MUHC)	Tatiana Carvalho (MUHC) ext. 43698 Ginette Ricard (MUHC) ext 43186 Josie Pepe (MUHC) ext 48186	
12	RCN		Spectral dual energy CT and textural radiogenomic analysis for optimal tumor delineation, patient staging, and biomarker for head and neck squamous cell carcinoma		Reza Forghani (JGH)	Assistant: Maryam Bayat	Ayat Salman ayat.salman@mail.mcgill.ca	
Salivary Gland								
13	RTOG 1008	NCT01220583	A randomized phase II/phase III study of adjuvant concurrent radiation and chemotherapy versus radiation alone in resected high-risk malignant salivary gland tumors	2/3	George Shenouda (MUHC)	Marianna Perna (MUHC)	Tatiana Carvalho (MUHC) ext. 43698 Ginette Ricard (MUHC) ext 43186 Josie Pepe (MUHC) ext 48186	
Thyroid								

PLEASE REFER TO SOLID TUMORS CLINICAL TRIAL LIST FOR MORE OPTIONS

14

		Developing and Implementing an Interdisciplinary Team-Based Approach for Patients with a Suspected or Confirmed Thyroid Cancer (ITCA-ThyCa)		Anthony Zeitouni (MUHC)			
--	--	---	--	-------------------------	--	--	--